Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | ENPP2 | Q13822 | 4/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 5/20 | 0.37 |
| ▸ | RAB9A | P51151 | 5/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.37 |
| ▸ | TTR | P02766 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29956883 | 1.00 | ALDH1A1 (0.45) | ALDH1A1CA1CA2ENPP2CA12 | |
| SCHEMBL4027923 | 0.95 | ADRA2A (0.42) | ALDH1A1CA1CA2ENPP2ADRA2A | |
| SCHEMBL12759201 | 0.91 | CA2 (0.43) | ALDH1A1CA1CA2ENPP2CA7 | |
| SCHEMBL8569648 | 0.79 | DRD1 (0.50) | — | |
| SCHEMBL13356016 | 0.78 | CA1 (0.34) | CA1CA2ENPP2TTR | |
| SCHEMBL2627980 | 0.77 | MAOA (0.61) | MEN1KMT2A | |
| SCHEMBL2627981 | 0.77 | MAOA (0.48) | ALDH1A1CA1CA2MEN1KMT2A | |
| SCHEMBL29951836 | 0.76 | ENPP2 (0.39) | ALDH1A1CA1CA2ENPP2TTR | |
| SCHEMBL3101723 | 0.74 | NPC1 (0.42) | ALDH1A1CA1CA2ENPP2NPC1 | |
| SCHEMBL6293921 | 0.74 | RXRA (0.40) | CA1CA2ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624003-B2 | Carboxylic acid containing indanyl compounds for the treatment of neurodegenerative diseases | CELGENE CORPORATION (US) | 2026-05-12 | — | — | US | disclosed |
| EP-4267117-B1 | CARBOXYLIC ACID CONTAINING INDANYL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | CELGENE CORP (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20240239776-A1 | AZASPIROCYCLES AS MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-18 | — | — | US | disclosed |
| US-20240228514-A1 | BORON-CONTAINING ORGANIC COMPOUND AND APPLICATIONS THEREOF | SHENZHEN CHINA STAR OPTOELECTRONICS SEMICONDUCTOR DISPLAY TECHNOLOGY CO., LTD. (CN) | 2024-07-11 | — | — | US | disclosed |
| US-20240228514-A1 | BORON-CONTAINING ORGANIC COMPOUND AND APPLICATIONS THEREOF | SHENZHEN CHINA STAR OPTOELECTRONICS SEMICONDUCTOR DISPLAY TECHNOLOGY CO., LTD. (CN) | 2024-07-11 | — | — | US | disclosed |
| US-20240124394-A1 | Carboxylic Acid Containing Indanyl Compounds for the Treatment of Neurodegenerative Diseases | CELGENE CORPORATION (US) | 2024-04-18 | — | — | US | disclosed |
| US-11897872-B2 | Azaspirocycles as monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2024-02-13 | — | — | US | disclosed |
| EP-4267117-A1 | CARBOXYLIC ACID CONTAINING INDANYL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | CELGENE CORPORATION (US) | 2023-11-01 | — | — | EP | disclosed |
| CN-116685313-A | Indanyl-containing carboxylic acid compounds for the treatment of neurodegenerative diseases | 细胞基因公司 | 2023-09-01 | — | — | CN | disclosed |
| US-20230227438-A1 | AZASPIROCYCLES AS MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-07-20 | — | — | US | disclosed |
| EP-1506190-B1 | (IMIDAZOL-1-YL-METHYL)-PYRIDAZINE AS NMDA RECEPTOR BLOCKER | HOFFMANN LA ROCHE (CH) | 2006-06-14 | — | — | EP | disclosed |
| US-7005432-B2 | Substituted imidazol-pyridazine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2006-02-28 | — | — | US | disclosed |
| EP-1506190-A1 | (IMIDAZOL-1-YL-METHYL)-PYRIDAZINE AS NMDA RECEPTOR BLOCKER | F. HOFFMANN-LA ROCHE AG (CH) | 2005-02-16 | — | — | EP | disclosed |
| EP-1036062-B1 | HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEASE (MMP) INHIBITORS | PFIZER LTD (GB) | 2004-01-02 | — | — | EP | disclosed |
| US-20030229096-A1 | Substituted imidazol-pyridazine derivatives | EVOTEC INTERNATIONAL GMBH (DE) | 2003-12-11 | — | — | US | disclosed |
| WO-2003097637-A1 | (IMIDAZOL-1-YL-METHYL)-PYRIDAZINE AS NMDA RECEPTOR BLOCKER | F. HOFFMANN-LA ROCHE AG (CH) | 2003-11-27 | — | — | WO | disclosed |
| US-6495568-B1 | TREATMENT OF TISSUE ULCERATION, WOUND REPAIR AND SKIN DISEASES | WARNER-LAMBERT COMPANY | 2002-12-17 | — | — | US | disclosed |
| EP-1036062-A1 | HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEASE (MMP) INHIBITORS | Pfizer Limited (GB) | 2000-09-20 | — | — | EP | disclosed |
| WO-1999029667-A1 | HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEASE (MMP) INHIBITORS | PFIZER LIMITED (GB) | 1999-06-17 | — | — | WO | disclosed |
| CN-1216980-A | Triaryl compounds | NOVARTIS AG (CH) | 1999-05-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228514-A1 | BORON-CONTAINING ORGANIC COMPOUND AND APPLICATIONS THEREOF | BCL6, SLCO4C1, SLCO2B1 | ALDH1A1 1928/4885CA1 2775/4885CA2 1453/4885 |
| US-20240239776-A1 | AZASPIROCYCLES AS MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, LPAR1 | ALDH1A1 245/4885CA1 2679/4885CA2 3285/4885 |
| US-11897872-B2 | Azaspirocycles as monoacylglycerol lipase modulators | MGLL, LPAR1, LPL | ALDH1A1 224/4885CA1 2710/4885CA2 3316/4885 |
| US-20230227438-A1 | AZASPIROCYCLES AS MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPAR1, LPL | ALDH1A1 224/4885CA1 2710/4885CA2 3316/4885 |
| US-12624003-B2 | Carboxylic acid containing indanyl compounds for the treatment of neurodegenerative diseases | S1PR5, LPAR5, S1PR2 | ALDH1A1 1387/4885CA1 610/4885CA2 188/4885 |
| US-20030229096-A1 | Substituted imidazol-pyridazine derivatives | GRIN2B, GRIN2A, GRIN2C | ALDH1A1 1634/4885CA1 2980/4885CA2 1927/4885 |
| US-20240124394-A1 | Carboxylic Acid Containing Indanyl Compounds for the Treatment of Neurodegenerative Diseases | S1PR5, S1PR2, LPAR5 | ALDH1A1 1229/4885CA1 1377/4885CA2 1487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.